open access

Vol 78, No 1 (2010)
EDITORIAL
Published online: 2010-01-29
Submitted: 2013-02-22
Get Citation

May the Force be with antileukotriene drugs

Andrzej Szczeklik
Pneumonol Alergol Pol 2010;78(1):1-2.

open access

Vol 78, No 1 (2010)
EDITORIAL
Published online: 2010-01-29
Submitted: 2013-02-22

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

May the Force be with antileukotriene drugs

Journal

Advances in Respiratory Medicine

Issue

Vol 78, No 1 (2010)

Pages

1-2

Published online

2010-01-29

Bibliographic record

Pneumonol Alergol Pol 2010;78(1):1-2.

Authors

Andrzej Szczeklik

References (15)
  1. Samuelsson B. The discovery of the leukotrienes. Am J Respir Crit Care Med. 2000; 161(2 Pt 2): S2–S6.
  2. Hui Y, Funk CD. Cysteinyl leukotriene receptors. Biochem Pharmacol. 2002; 64(11): 1549–1557.
  3. Ciana P, Fumagalli M, Trincavelli ML, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006; 25(19): 4615–4627.
  4. Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet. 1997; 350(9091): 1599–1600.
  5. Szczeklik A, Nizankowska-Mogilnicka E, Sanak M. Hypersensitivity to aspirin and nonsteroidal anti-inflammatory drugs. In: Adkinson NF, Busse WW, Bochner BS, Holgate ST, Simons FER. ed. Middleton’s Allergy. Wyd. 7. Simons & Lemanske, Mosby Elsevier 2009: 1227–1243.
  6. Park HS, Kim SH, Sampson AP, et al. The HLA-DPB1*0301 marker might predict the requirement for leukotriene receptor antagonist in patients with aspirin-intolerant asthma. J Allergy Clin Immunol. 2004; 114(3): 688–689.
  7. Szczeklik A, Mastalerz L, Nizankowska E, et al. Montelukast for persistent asthma. Lancet. 2001; 358(9291): 1456–1457.
  8. Mastalerz L, Nizankowska E, Sanak M, et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest. 2002; 32(12): 949–955.
  9. Dahlén B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1998; 157(4 Pt 1): 1187–1194.
  10. O'Connor BJ, Löfdahl CG, Balter M, et al. Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. Respir Med. 2007; 101(6): 1088–1096.
  11. Sanak M, Dropinski J, Sokolowska B, et al. Pharmacological inhibition of leukotriene biosynthesis: effects on the heart conductance. J Physiol Pharmacol. 2010; 61(1): 53–58.
  12. Szczeklik A, Nizankowska E, Mastalerz L, et al. Myocardial ischemia possibly mediated by cysteinyl leukotrienes. J Allergy Clin Immunol. 2002; 109(3): 572–573.
  13. Jawien J, Gajda M, Wołkow P, et al. The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. J Physiol Pharmacol. 2008; 59(3): 633–639.
  14. Rzeszutko M, Kaczmarek P, Nowakowski T, et al. Precutaneous coronary intervention is associated with overproduction of cysteinyl leukotrienes. Eur. Heart J. 2006; 27(supl.): 227.
  15. Hlawaty H, Jacob MP, Louedec L, et al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler Thromb Vasc Biol. 2009; 29(4): 518–524.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl